Search ADAPY
Adaptimmune Therapeutics PLC
OTC Markets OTCPK · CIK 1621227
Last close0.04
Daily change-0.00 (-2.63%)
10 Years gain-99.44%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ADAPY · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
75.2Momentum
100.0Acceleration
100.0Confidence
76.0Annual Revenue11
Quarterly Revenue36
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality18.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet12.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 200.126 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 9.1839%.
Key Metrics
Revenue Growth TTM189.21%OK
Revenue CAGR 3Y207.07%OK
Gross Margin98.22%OK
Operating Margin-11.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y65.63%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y9.18%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 FY Dec 31, 2024 | $178.03M | $177.96M | -$68.76M | -$73.21M | -$74.09M | 99.96% | -38.62% | -41.62% | n/a | 1.51B |
| 2024 FY Dec 31, 2023 | $60.28M | $60.28M | -$139.74M | -$140.88M | -$145.56M | 100% | -231.82% | -241.47% | n/a | 1.21B |
| 2024 FY Dec 31, 2022 | $27.15M | $27.15M | -$163.97M | -$141.77M | -$171.27M | 100% | -603.97% | -630.86% | n/a | 967.24M |
| 2023 FY Dec 31, 2021 | $6.15M | n/a | -$162.25M | $10.73M | $2.16M | n/a | -2,638.58% | 35.05% | n/a | 934.83M |
| 2022 FY Dec 31, 2020 | $3.96M | n/a | -$133.41M | -$53.59M | -$55.93M | n/a | -3,370.52% | -1,413.14% | -2,966.22% | 854.78M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $190.09M | sum latest 4 fiscal quarters Revenue | OK | 0001558370-25-011307, 0001558370-24-015532 |
| Revenue Growth TTM | 189.21% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001558370-25-011307, 0001558370-24-015532 |
| Revenue CAGR 3Y | 207.07% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001558370-25-003544 |
| Revenue CAGR 5Y | 175.49% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001558370-25-003544 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001558370-25-003544 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001558370-25-011307, 0001558370-24-015532 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 98.22% | Gross Profit / Revenue | OK | 0001558370-25-011307, 0001558370-24-015532 |
| Operating Margin | -11.57% | Operating Income / Revenue | OK | 0001558370-25-011307, 0001558370-24-015532 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001558370-25-011307 |
| Current Ratio | 1.52x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.02x | (Cash + Short-term Investments) / Total Debt | OK | 0001558370-25-011307 |
| Revenue per Diluted Share | $0.12 | Revenue / Diluted Shares | OK | 0001558370-25-011307, 0001558370-24-015532 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |